Cargando…

Roles for hENT1 and dCK in gemcitabine sensitivity and malignancy of meningioma

BACKGROUND: High-grade meningiomas are aggressive tumors with high morbidity and mortality rates that frequently recur even after surgery and adjuvant radiotherapy. However, limited information is currently available on the biology of these tumors, and no alternative adjuvant treatment options exist...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yamamoto, Masahiro, Sanomachi, Tomomi, Suzuki, Shuhei, Uchida, Hiroyuki, Yonezawa, Hajime, Higa, Nayuta, Takajo, Tomoko, Yamada, Yuki, Sugai, Asuka, Togashi, Keita, Seino, Shizuka, Okada, Masashi, Sonoda, Yukihiko, Hirano, Hirofumi, Yoshimoto, Koji, Kitanaka, Chifumi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Basic and Translational Investigations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168817/ https://www.ncbi.nlm.nih.gov/pubmed/33556172 http://dx.doi.org/10.1093/neuonc/noab015

Ejemplares similares

ET-7 Roles for hENT1 and dCK in gemcitabine sensitivity and malignancy of meningioma
por: Yamamoto, Masahiro, et al.
Publicado: (2021)

Gemcitabine radiosensitization primes irradiated malignant meningioma cells for senolytic elimination by navitoclax
por: Yamamoto, Masahiro, et al.
Publicado: (2021)

Dexamethasone Sensitizes Cancer Stem Cells to Gemcitabine and 5-Fluorouracil by Increasing Reactive Oxygen Species Production through NRF2 Reduction
por: Suzuki, Shuhei, et al.
Publicado: (2021)

Prognostic effect of hENT1, dCK and HuR expression by morphological type in periampullary adenocarcinoma, including pancreatic cancer
por: Elebro, Jacob, et al.
Publicado: (2016)

Gene expression of hENT1, dCK, CDA, dCMPD and topoisomerase IIα as an indicator of chemotherapy response in AML treated with cytarabine and daunorubicin
por: Kulsoom, Bibi, et al.
Publicado: (2018)

Brexpiprazole, a Serotonin-Dopamine Activity Modulator, Can Sensitize Glioma Stem Cells to Osimertinib, a Third-Generation EGFR-TKI, via Survivin Reduction
por: Suzuki, Shuhei, et al.
Publicado: (2019)

In vitro and in vivo anti-tumor effects of brexpiprazole, a newly-developed serotonin-dopamine activity modulator with an improved safety profile
por: Suzuki, Shuhei, et al.
Publicado: (2019)

Doxazosin, a Classic Alpha 1-Adrenoceptor Antagonist, Overcomes Osimertinib Resistance in Cancer Cells via the Upregulation of Autophagy as Drug Repurposing
por: Suzuki, Shuhei, et al.
Publicado: (2020)

Spironolactone, a Classic Potassium-Sparing Diuretic, Reduces Survivin Expression and Chemosensitizes Cancer Cells to Non-DNA-Damaging Anticancer Drugs
por: Sanomachi, Tomomi, et al.
Publicado: (2019)

Therapeutic targeting of pancreatic cancer stem cells by dexamethasone modulation of the MKP-1–JNK axis
por: Suzuki, Shuhei, et al.
Publicado: (2021)

Antitumor activity of gemcitabine against high-grade meningioma in vitro and in vivo
por: Takeda, Hiroyuki, et al.
Publicado: (2017)

hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status
por: Raffenne, Jerome, et al.
Publicado: (2019)

Gemcitabine Cooperates with Everolimus to Inhibit the Growth of and Sensitize Malignant Meningioma Cells to Apoptosis Induced by Navitoclax, an Inhibitor of Anti-Apoptotic BCL-2 Family Proteins
por: Yamamoto, Masahiro, et al.
Publicado: (2022)

hENT-1 Expression and Localization Predict Outcome After Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients
por: Meijer, Laura L., et al.
Publicado: (2016)

Antagonizing MDM2 Overexpression Induced by MDM4 Inhibitor CEP-1347 Effectively Reactivates Wild-Type p53 in Malignant Brain Tumor Cells
por: Mitobe, Yuta, et al.
Publicado: (2023)

The Novel MDM4 Inhibitor CEP-1347 Activates the p53 Pathway and Blocks Malignant Meningioma Growth In Vitro and In Vivo
por: Mitobe, Yuta, et al.
Publicado: (2023)

Antitumor effect of gemcitabine-loaded albumin nanoparticle on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression
por: Guo, Zhongyi, et al.
Publicado: (2018)

Repositioning CEP-1347, a chemical agent originally developed for the treatment of Parkinson’s disease, as an anti-cancer stem cell drug
por: Okada, Masashi, et al.
Publicado: (2017)

hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA
por: Aughton, Karen, et al.
Publicado: (2021)

hENT1’s role in adjuvant intra-arterial gemcitabine-based chemotherapy for resectable pancreatic cancer patients
por: Wang, Wei, et al.
Publicado: (2023)

Involvement of GLUT1-mediated glucose transport and metabolism in gefitinib resistance of non-small-cell lung cancer cells
por: Suzuki, Shuhei, et al.
Publicado: (2018)

Combination treatment with hENT1 and miR-143 reverses gemcitabine resistance in triple-negative breast cancer
por: Xi, Yue, et al.
Publicado: (2022)

dCK Expression and Gene Polymorphism With Gemcitabine Chemosensitivity in Patients With Pancreatic Ductal Adenocarcinoma: A Strobe-Compliant Observational Study
por: Xiong, Junjie, et al.
Publicado: (2016)

The Role of Deoxycytidine Kinase (dCK) in Radiation-Induced Cell Death
por: Zhong, Rui, et al.
Publicado: (2016)

Human equilibrative nucleoside transporter 1 (hENT1) expression as a predictive biomarker for gemcitabine chemotherapy in biliary tract cancer
por: Kim, Jaihwan, et al.
Publicado: (2018)

Targeting Folate Metabolism Is Selectively Cytotoxic to Glioma Stem Cells and Effectively Cooperates with Differentiation Therapy to Eliminate Tumor-Initiating Cells in Glioma Xenografts
por: Okada, Masashi, et al.
Publicado: (2021)

Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer
por: Elander, N. O., et al.
Publicado: (2018)

dCK negatively regulates the NRF2/ARE axis and ROS production in pancreatic cancer
por: Hu, Qiangsheng, et al.
Publicado: (2018)

Licochalcone A specifically induces cell death in glioma stem cells via mitochondrial dysfunction
por: Kuramoto, Kenta, et al.
Publicado: (2017)

Inhibition of the Lipid Droplet–Peroxisome Proliferator-Activated Receptor α Axis Suppresses Cancer Stem Cell Properties
por: Kuramoto, Kenta, et al.
Publicado: (2021)

Inhibition of the Phospholipase Cε–c-Jun N-Terminal Kinase Axis Suppresses Glioma Stem Cell Properties
por: Okada, Masashi, et al.
Publicado: (2022)

Domatinostat Targets the FOXM1–Survivin Axis to Reduce the Viability of Ovarian Cancer Cells Alone and in Combination with Chemotherapeutic Agents
por: Nakagawa-Saito, Yurika, et al.
Publicado: (2023)

Decreased erythrocyte nucleoside transport and hENT1 transporter expression in glucose 6-phosphate dehydrogenase deficiency
por: Al-Ansari, Mohammad, et al.
Publicado: (2015)

Human Equilibrative Nucleoside Transporter 1 (hENT1) in Pancreatic Adenocarcinoma: Towards Individualized Treatment Decisions
por: Spratlin, Jennifer L., et al.
Publicado: (2010)

ET-6 Gemcitabine radiosensitization primes irradiated malignant meningioma cells for senolytic elimination by navitoclax
por: Yamamoto, Masahiro, et al.
Publicado: (2021)

HDAC Class I Inhibitor Domatinostat Preferentially Targets Glioma Stem Cells over Their Differentiated Progeny
por: Nakagawa-Saito, Yurika, et al.
Publicado: (2022)

Targeting the K-Ras - JNK axis eliminates cancer stem-like cells and prevents pancreatic tumor formation
por: Okada, Masashi, et al.
Publicado: (2014)

Targeting the facilitative glucose transporter GLUT1 inhibits the self-renewal and tumor-initiating capacity of cancer stem cells
por: Shibuya, Keita, et al.
Publicado: (2014)

A sellar neuroblastoma showing rapid growth and causing syndrome of inappropriate secretion of antidiuretic hormone: A case report
por: Kamil, Muhammad, et al.
Publicado: (2020)

Targeting AHR Increases Pancreatic Cancer Cell Sensitivity to Gemcitabine through the ELAVL1-DCK Pathway
por: Stukas, Darius, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_uf8igabfgjlkecj0c8btrq4jl7